Functional variomics provides the foundation for personalized medicine by linking genetic variation to disease expression, outcome and treatment, yet its utility is dependent on appropriate assays to evaluate mutation impact on protein function. To fully assess the effects of 106 missense and nonsense variants of PTEN associated with autism spectrum disorder, somatic cancer and PHTS, we take a deep phenotypic profiling approach using 18 assays in 5 model systems spanning diverse cellular environments ranging from molecular function to neuronal morphogenesis and behavior. Variants inducing instability occurred across the protein, resulting in partial to complete loss of function (LoF), which was well correlated across models. However, assays were selectively sensitive to variants located in substrate binding and catalytic domains, which exhibited complete LoF or dominant negativity independent of effects on stability. Our results indicate that full characterization of variant impact requires assays sensitive to instability and a range of protein functions.
INTRODUCTION
Autism spectrum disorder (ASD) is the most common genetic neurodevelopmental disorder, characterized by impaired social communication and restricted, repetitive behaviors 1 . Headway in understanding ASD pathophysiology has been stymied by tremendous phenotypic heterogeneity and complex genetics across individuals. Conclusively linking genes to ASD is challenging since sequencing efforts have identified mutations in hundreds of genes from individuals with the disorder [2] [3] [4] [5] [6] [7] [8] [9] . Confidence of gene association to ASD is enhanced by identification of de novo, likely gene disrupting (LGD) mutations; however, the most common de novo mutations identified in individuals with ASD are missense (MS) variants of unknown significance (VUS) 2, 9 . A complete understanding of ASD genetics and their link to pathophysiology requires deciphering how these mutations impact protein function, and how protein dysfunction affects neural circuits and behavior 10 .
The lipid and protein phosphatase, PTEN (phosphatase and tensin homologue deleted on chromosome 10), has well-established links to ASD 11 , somatic cancers 12 , and the cancerpredisposing PTEN hamartoma syndrome (PHTS) 13, 14 . However, while LGD mutations in PTEN have been found in individuals with ASD, the majority of variants identified are MS VUS, and their impact on protein function and causal links to the molecular mechanism(s) of disease expression remain unclear. Understanding the specific impact of these point mutations on PTEN function and their repercussions in cellular and tissue development is necessary for relating its disruption to disease.
As PTEN is a multifunctional protein expressed throughout the body, and both cancer and ASD are complex conditions involving diverse tissues, it is likely that VUS may disrupt distinct PTEN functions in different cell types and developmental conditions to contribute to disease. Saturation mutagenesis and massively parallel functional approaches to characterize single nucleotide variants of PTEN have identified a large range of impacts on PTEN's lipid phosphatase activity using single-cell assays 15, 16 . In order to more comprehensively assess a full range of PTEN functions, here we take a novel deep phenotypic profiling approach by assessing the impact of MS and nonsense (NS) variants in 18 bioassays in 5 model systems. Applying high-throughput unbiased analyses of genetic interactions of human PTEN in Saccharomyces cerevisiae we develop a novel assay of PTEN variant function sensitive to lipid phosphatase activity. By expressing human PTEN variants in Drosophila melanogaster we assess the rate of development in an invertebrate model, regulated by the insulin receptor pathways 17, 18 . We test a smaller subset of PTEN variants for effects on neuronal dendritic and axonal growth, and excitatory and inhibitory synaptogenesis using rat primary neuronal cultures, processes found to be disrupted in ASD models 19, 20 and mediated by both lipid and protein phosphatase PTEN activities 21, 22 . As ASD is primarily defined as disordered behavior and sensorimotor processing, we test impact of variants on chemotaxis in Caenorhabditis elegans. In order to probe the molecular mechanisms causing variant dysfunction in these assays, we performed flow cytometry analysis of human embryonic kidney (HEK293) cells overexpressing PTEN variants to parse effects on protein stability and catalytic activity. These multi-model results provide robust validation of measures of variant function in highly diverse cellular environments to uncover complexities of the contribution of single nucleotide mutations to protein dysfunction and pathophysiology.
RESULTS

Categorization of PTEN variants
We selected PTEN MS and NS mutations identified in individuals with ASD, intellectual disability (ID), developmental delay (DD), somatic cancer and PHTS, as well as variants found among the general population (Fig 1a, Supp. Table 1 ). We categorized a total of 48 variants as ASD (15 de novo) found in cases of ASD, ID, or DD. A set of 4 MS variants were classified as Somatic Cancer which have not been reported in ASD, but exhibit a high frequency of reports in the COSMIC database 23 . A further 19 variants termed PHTS were found in individuals with PHTS, but not ASD and low frequency in somatic cancer. There is high overlap in variant incidence across these disorders ( Fig. 1b) . We included 5 PTEN variants with well-characterized disruptions on protein function, termed Biochemical Variants. These include C124S, which is both protein-and lipidphosphatase catalytically inactive 24 ; G129E, a lipid phosphatase-dead variant 25 ; Y138L, a protein phosphatase-dead variant 26 ; 4A, in which the four phosphorylation sites Ser 380 , Thr 382 , Thr 383 and Ser 385 were replaced with alanines, creating a phospho-null construct lacking self-repression, rendering it constitutively active 27 ; and C124S-4A which contains both catalytic inactive and phospho-null mutations 22 . C124S has also been found in somatic cancer 23 , and G129E has been found in macrocephaly, DD 28 , PHTS 29 , and somatic cancer 23 . In order to understand the range of PTEN protein function existing in the general population, 8 variants were selected based on their relatively high frequency in the gnomAD database 30 , termed Population Variants. Additionally, in order to test the quality of common predictive algorithms of protein dysfunction, variants were included with either Predicted High Impact (17) or Predicted Low Impact (5) as determined by CADD phred version 1.0 31 or SNAP2 scores 32 . We also included 2 NS mutations, R130X and R335X, due to their common association with ASD, PHTS and somatic cancer. Many variants exist in multiple categories, and the full variants classification, reference, and CADD phred and SNAP2 scores can be found in Supp. Table 1 . We use the NCBI reference sequence of PTEN (NM_000314.7) as wildtype (WT).
PTEN overexpression in yeast reveals novel genetic interactions and provides assessment of lipid phosphatase function
We first took advantage of the high-throughput capacity of the Saccharomyces cerevisiae synthetic dosage lethality screen 33 as an unbiased assay to identify genetic interactions of PTEN. By overexpressing human WT PTEN (WT), empty vector (EV), or the catalytically-inactive variant C124S, in approximately 5000 non-essential gene mutant strains of the yeast deletion collection 34 , we identified 44 potential genetic interactions of PTEN. Through further testing, 8 gene deletion mutants, deemed 'sentinels', were selected for inclusion in our assay which show significant, strong negative genetic interactions with WT, but not EV or C124S (Fig. 1c) . In each of these deletion strains, overexpression of WT resulted in a reduction in colony growth. The sentinel proteins Vac7 and Vac14 physically interact and promote the synthesis of PI(3,5)P2 by activating Fab1, a kinase for PI3P 35, 36 (Fig. 1d) . The sentinel protein Fig4, when recruited to the vacuolar membrane by Vac14, dephosphorylates PI(3,5)P2 to form PI3P 36 . Therefore, lack of any of these three genes results in altered PI3P metabolism. Likewise, the other 6 deletion mutant proteins directly or indirectly influence PI3P signaling 37 . For example, Vam3 and Vam7 are SNARE proteins and Ypt7 is a Rab GTPase. All three are components of the vacuolar fusion complex 38-41 , in which Vam7 directly binds PI3P on the vacuolar membrane to initiate fusion 42 . While yeast does not contain the primary PTEN substrate, PIP3, nor an endogenous PTEN homolog, PTEN also binds PI3P, which is present in yeast, via its C2-domain in the recruitment of cytoplasmic PTEN to the endosomal membrane 43 . Altogether, we hypothesize that PTEN utilizes PI3P as a substrate in yeast and antagonizes already compromised PI3P levels in these mutants.
Next, we designed a novel mini-array platform to screen the genetic interactions of WT, EV, and 99 PTEN variants with each of the 8 sentinel strains. As a representative data set, we present results for the yeast strain lacking Vac14 (Δvac14), which shows the strongest genetic interaction with PTEN and allows for the greatest dynamic range to study the effects of PTEN variants ( Fig. 1e; these and all other results also listed in Supp. Table 2 ). We find that using the Δvac14 sentinel, 37 variants, including 22 of 47 ASD-associated variants tested, exhibit complete LoF, with 6 being below LoF. 27 variants retained partial function while 35 variants, including 8 ASD, retained WTlike functionality. Similar results were found with the 7 other sentinels (Supp. Fig. 1 ; Supp. Table   3 ).
PTEN variants delay developmental rate in Drosophila
We generated 88 transgenic lines of Drosophila melanogaster expressing WT human PTEN, 86 PTEN variants, and an EV control, each integrated into the attP2 locus 44 allowing confident quantitative comparison of relative function between all variants by virtue of their equivalent expression levels. In Drosophila, reduced insulin receptor signaling slows developmental rate, causing delay in pupa formation and eclosion -the emergence of the adult fly from the pupa 18, 45 ( Fig. 2a) . Given PTEN's function in counteracting insulin signaling, we found that overexpression of WT in Drosophila in all cells throughout development, led to a significant delay in time to eclosion compared to EV, which was not observed in flies expressing C124S (Fig. 2b) . We then screened 86 PTEN variants, including 45 ASD to compare time to eclosion against one another, EV (normalized as 0) and to WT (normalized as 1) ( Fig. 2c) . Variants exhibited a range of functionality: with 41/86 variants being complete LoF, including 26 ASD. 34/86 were partial LoF, or hypomorphic, and 11/86 variants retained WT functionality. We also observed 2 variants, the PHTS N117S and Q298E, which slowed developmental rate further than that of WT, while the known gain of function (GoF) variant 4A induced lethality. Finally, we noted 6/86 variants, including the lipid phosphatase dead G129E exhibited eclosion significantly faster than EV. We find a high level of concordance (Pearson r = 0.69, p<0.0001) between functional measures of Δvac14 genetic interactions in yeast and development in fly ( Fig. 2d) .
PTEN variants impact neural development in rat primary cultures
Aberrant neuronal morphology and excitatory/inhibitory synapse balance are hallmarks of ASD 46 , and ASD rodent models 20 . Reducing PTEN expression results in increased neuronal growth, with larger soma size, increased dendritic and axonal branch length, and increased excitatory, but not inhibitory synapse density 22, [47] [48] [49] [50] [51] . To assay variant function in these ASD-associated neuronal growth processes, we overexpressed WT and 19 PTEN variants, or GFP alone, in rat primary hippocampal and dorsal root ganglion (DRG) neuronal cultures. We find that overexpression of WT induced the opposite effects observed by reducing PTEN, including decreased density of PSD95 puncta, a marker of excitatory glutamatergic synapses (Fig. 3a,c) , but had no impact on density of the inhibitory GABAergic synapse marker Gephyrin (Fig. 3a) . WT induced a significant reduction of soma size and both total dendritic arbor and axonal lengths ( Fig. 3b,d- displayed a varying amount of dysfunction, with 10 variants exhibiting significant LoF compared to WT. C124S and two ASD variants, I101T and G132D, increased soma size more than GFP. The Population Variant D268E appeared WT-like in all four measures of neuronal growth and synaptogenesis. Notably, the PHTS variant A79T, which is also found at increased frequency in gnomAD, exhibited a GoF phenotype in axonal growth and complete or less than LoF for PSD95 density and dendrite length.
PTEN variant effects on sensory processing and behavior in C. elegans
Since ASD is a behaviorally diagnosed disorder, and because deficits in sensory processing are a core feature of ASD present in >95% of cases 58 , we tested the effects of PTEN variants on sensorimotor neural circuit function in an intact animal model. We used a behavioral assay in C. elegans as they have a unique advantage of being the only animal known to survive homozygous null mutations in PTEN, allowing us to directly assess the functional consequences of PTEN variants in a transgenic rescue assay in vivo 52 . C. elegans exhibit robust navigation up a concentration gradient toward a point source of NaCl. Worms harboring NS mutations in the PTEN homolog, daf-18, exhibit a complete reversal in NaCl chemotaxis due to a dysregulation in the insulin pathway acting on a single sensory neuron (Fig 3g) 59, 60 . Pan-neuronal expression of WT human PTEN in daf-18 mutants was sufficient to rescue normal chemotaxis. We then used our machine vision system, the Multi-Worm Tracker 53 to automatically quantify chemotaxis in large populations of animals. We overexpressed the same WT and 19 PTEN variants tested in rat neuronal cultures in daf-18 mutant worms and found that 14/19 variants, including C124S exhibit complete LoF, while T167N, Y176C and D268E showed partial LoF, and A79T and P354Q retained WT-like function (Fig 3h) . The ASD variant G132D exhibited stronger negative chemotaxis than daf-18 mutants.
Protein instability is a major mechanism of variant PTEN dysfunction
To identify molecular mechanisms underlying variable effects of MS variants, we measured impact on protein stability, a known mechanism of PTEN dysfunction 15, 27 . We first measured PTEN protein abundance for WT and 97 variants tested in yeast using western blot analysis ( Fig.   4a ) and found a significant reduction in PTEN levels for 31 variants compared to WT, with 21 variants having stability below 50% of WT. Notably, of 46 ASD variants measured, nearly half (22/46) had significantly reduced levels of PTEN. To examine whether the changes in protein abundance assessed in yeast is reflected in a human cellular environment, we overexpressed WT and 105 variants as sfGFP fusion proteins in HEK293 cells, with the red fluorophore mTagRFP-T co-expressed from the same plasmid. The green-to-red ratio for each cell was quantified using flow cytometry, with a decrease from WT level indicating reduced protein stability ( Fig. 4b-d ).
77/105 variants were significantly less stable than WT, of which 50 exhibited stability of 50% or less than WT. 19/105 showed WT-like stability, and 9/105 were significantly more stable. Of the 47 ASD variants tested, most (40/47) were significantly less stable than WT, and 29 exhibited less than 50% WT stability. Only 5, P354Q, R130L, R15S, R14G and T78A, were not significantly different from WT. The variants H93Y and K6E were hyper-stable. Interestingly, all of the Biochemical Variants exhibited significant protein instability. PTEN stability in yeast and HEK293 cells were well correlated ( Fig. 4e , Pearson r = 0.55, p<0.001) and results indicate that instability of PTEN protein is a major mechanism of single nucleotide variation-induced dysfunction.
PTEN reduction of pAKT/AKT in HEK293 cells identifies 25 novel dominant negative variants
PTEN functions as a negative regulator of the PI3-AKT signaling pathway by decreasing the pool of available PI(3,4,5)P3 via its lipid phosphatase activity, causing a reduction in the level of activated, phosphorylated AKT (pAKT) 54, 55 . To assess the lipid phosphatase function of WT PTEN and 105 variants, we measured levels of pAKT/AKT in insulin-treated HEK293 cells using flow cytometry ( Fig. 5a-c) . As expected, overexpression of WT decreases pAKT levels in an exogenous PTEN expression level-dependent manner ( Fig. 5a ). 25/105 variants showed complete LoF and 19/105 showed partial LoF. 29/105 variants retained WT-like function, and P354Q, Q396R and the constitutively active 4A, exhibited a GoF phenotype. Further, 65/105 variants had <50% functionality, including 42/47 ASD. Expression of C124S or G129E raised pAKT/AKT levels ( Fig. 5c) , consistent with a dominant negative phenotype, as reported previously 15, 21, 56, 57 .
Here, we identify 27 additional variants (25 novel) exhibiting dominant negative activity, including 17 ASD. To further investigate these phenotypes, we used CRISPR/Cas9 to create a biallelic knockout of PTEN (PTEN-KO) in HEK293 cells and repeated the pAKT/AKT assay for 32 variants. For 21 of 28 variants exhibiting dominant negative activity in parental cells, the absence of endogenous PTEN abrogated this effect ( Fig. 5d) . Interestingly, the GoF of constitutively active 4A was markedly reduced in PTEN-KO, yet still significantly more active than WT, suggesting it may enhance endogenous PTEN activity when present. We found only 6/32 variants tested (A126P, H123Q, P38H, R130Q, A126D and R130L) exhibiting greater than 10% change in stability between parental and PTEN-KO cells suggesting that interactions with endogenous PTEN had minimal influence on variant stability (Supp. Fig. 2) .
Varied functional correlations for variants within stability-dependent or -independent domains
Overall, we find a range of strength of correlation between assays and model systems (Supp. Fig.   3 ), with strongest correlations observed between the 8 yeast sentinels, and between the HEK293 pAKT/AKT assay and yeast genetic interactions ( Fig. 5e ; Pearson r = 0.79, p<0.0001 for Δvac14), fly development ( Fig. 5f ; Pearson r = 0.78, p<0.0001), rat axonal outgrowth (Pearson r = 0.73. p<0.001), and worm sensorimotor behavior (Pearson r = 0.82, p<0.0001). Other cross-assay andmodel comparisons showed limited concordance.
In order to identify features of variant impact contributing to varied phenotypes in different assays we investigated the relationship between protein function and stability. To determine whether function directly tracks stability we subtracted the normalized stability (nS) of each variant from its normalized function value (nF) in each assay. If function directly follows stability then nF-nS≈0, while values closer to 1 or -1 would suggest function/dysfunction independent of stability.
Positive values indicate variants with greater function than predicted from stability, while negative values indicate variants with less function than predicted from stability. We used measures of protein abundance in yeast for nS for yeast, and stability measures in HEK293 for all other assays.
Interestingly, we find domains within PTEN in which variants predominantly exhibited either stability-independent function (nF-nS<>0), or stability-dependent function (nF-nS≈0) ( Fig. 6a,b) .
Stability-independent domains, encompassing variants which largely exhibit greater dysfunction than predicted from their instability (nF-nS≈-1), are associated with previously well-characterized substrate binding and catalytic domains including within the N-terminal phosphatase and the PIP3binding domain (PBD) (amino acid (AA) positions 1-55); the WPD-loop (AA 92-93); and the Ploop (AA 123-131) 58 . Therefore, we define stability-independent domains as AA 1-55, 92-93, and 123-131, and variants outside these regions, largely exhibiting nF-nS ≈ 0, as being in stabilitydependent domains (Fig. 6a,b) . Variants within these 2 groups showed distinct distributions when plotting the frequency of nF-nS values ( Fig. 6c) . Plotting the HEK293 pAKT/AKT function against stability reveals that for variants in stability-dependent domains function levels track with stability, yielding a range of function from WT to partial and full LoF (Fig. 6d ). For these variants, instability is likely the primary molecular mechanism underlying dysfunction. In contrast, variants within stability-independent domains exhibit complete LoF or dominant negativity irrespective of level of instability, likely indicating molecular mechanisms of dysfunction associated with aberrant substrate binding or catalytic activity. We find similar distributions of nF-nS values using data from yeast or combining results from all models (Supp. Fig. 4) , and when removing variants with function and stability values not significantly different from WT (Supp. Fig. 4f ).
Repeating correlation analyses for variant impact between assays produces dramatically different
results when comparing variants within stability-dependent and -independent domains ( Fig. 6e,f; Supp. Fig. 5a,b ). Correlations were high between all assays for variants within stability-dependent domains, indicating that mechanisms of protein instability are independent of model system.
Correlations for variants in stability-independent domains, however, were poor across models, suggesting that different assay are selectively sensitive to dysfunction of different substrate binding and catalytic domains.
Relationship of PTEN variant dysfunction and disease
Attempts to associate MS induced dysfunction to specific disease states is a major role for functional variomics for PTEN, however, this goal is challenged by variants selection bias and high overlap of the same variants occurring in different disorders. To investigate this relationship with data from our multiple assays, we reclassify variants as ASD or PHTS if they have been identified in any individual with these disorders (including ID or DD in ASD), and as Somatic Cancer if variants have 8 or more cases reported in COSMIC. For this analysis, we allow the same variants to be in multiple classes. Of the 106 PTEN variants we tested, 49 have been identified in individuals with ASD, DD or ID, with 40/49 also found in PHTS, 15/49 in somatic cancer, and 14/49 in all three disorders ( Fig. 1b are Somatic Cancer, and 18 found in both disorders. We find that in yeast and HEK293 lipid phosphatase assays, ASD, PHTS and Somatic Cancer variants all performed significantly worse than Population Variants. However, no significant difference was found for variant function between these disorders, except between PHTS and Somatic Cancer in the HEK293 pAKT/AKT assay (Supp. Fig. 6a ), but this difference was lost when variants we determined to be 'likely benign' due to WT stability and function in multiple models (below) were removed from analysis (Supp. Fig. 6b ). We note that this analysis relies on assumptions of disease causality that are uncertain, so we interpret the negative result as inconclusive on the question of whether there are disease-specific differences in PTEN variant effects. In contrast to between-disorder comparisons, we find that variant impact on function in the yeast, fly and HEK293 assays all show significant predictive powers when stratified by their frequency of occurrence in somatic cancers as reported in COSMIC ( Fig. 7) .
Assessment of predictive algorithms
We set out to test the value of algorithms for predicting variant dysfunction by testing variants with predicted low or high LoF in CADD phred and SNAP2, computational tools that integrate multiple annotations to quantitatively predict deleterious mutations 31, 32 . For variants in the Predicted Low Impact group, both CADD and SNAP2 scores were accurate for Δvac14 yeast, and HEK293 pAKT/AKT assays, but are less accurate predicting results of the fly eclosion assay (Supp. Fig. 7) . The accuracy of predictions for Predicted High Impact variants were more variable. In general, CADD and SNAP2 scores correlate well with our functional assessments, but both are biased toward reporting dysfunction. For example, in ASD variants D107G, L70V, T167N, and Y65C, CADD predicts they are more pathogenic than at least 99% of all other mutations in the genome while SNAP2 predicts a more intermediate effect. However, these variants have WT-like levels of function in our assays.
High-confidence variant classification
We classified 106 PTEN variants according to their impacts on 8 functional assays encompassing a range of phenotypes between dominant negative to GoF, and 2 abundance/stability assays ( Fig.   8a ). Next, we classified variants following a binary LoF/WT-classifications with a cut-off for LoF at <50% of WT function 59 (Fig. 8b) . For each variant, a score from 0 to 1 is then obtained by dividing the number of LoF assays by the number of assays performed, and then classified as follows: Likely Benign variants have scores <0. 25 and are WT-like in at least two assays; Likely Pathogenic have scores > 0.5 and are LoF in at least two assays; Pathogenic have scores ≥0.75 and are LoF in at least three assays; and VUS have scores ≥0.25, but <0.5 or too little assay data yielding conflicting results. Stability was only included in discerning variant profiling for unstable proteins, since WT-like stability is not predictive of WT-like function, but instability correlates with dysfunction.
Of the 106 variants tested, we classify 50 as Pathogenic, including 31 ASD. We further classify 10 variants, including 4 ASD, as Likely Pathogenic. We consider 24 variants to be Likely Benign, including 3 ASD: P354Q, T202I and T78A; and 12 PHTS: I135V, N340H, N356D, K402N, N117S, Y180H, I203V, Q298E, N340D, K342N, L345V and I400V. We are unable to make a functional classification for 22 variants due to either insufficient data or conflicting results between assays and thus retain the classification of VUS. These include the ASD variants M35V, L70V, H123Q, E157G, C211W, W274L, Y176C and Y65C, as well as the PHTS variants A79T, N228S and S229T.
DISCUSSION
We have taken a deep phenotyping approach to comprehensively assess the impact of single amino acid changes to PTEN function. We use 5 phylogenetically diverse model systems and phenotypes spanning molecular function to behavior in order to measure variant impact on the multiple complex roles of this protein. By taking advantage of the high-throughput nature of yeast, fly, and HEK293 models, we are able to conduct in-depth analyses of ~100 variants, allowing comparison of effects of overexpression in highly diverse cellular environments. These high-throughput assays allowed selection of a smaller subset of variants exhibiting a range of dysfunction phenotypes to test in lower-throughput neuronal and behavioral assays with more direct relevance to ASD pathophysiology. By utilizing a multi-model system approach including measures of protein stability and function, we identify a diversity of variant impact caused by distinct molecular mechanisms, which would not be apparent from single-model approaches.
As previously reported 15 , we find that PTEN variants commonly decrease protein stability. We find that MS variants induce a full range of instability, which was largely consistent between yeast and HEK293 models. Further, for ~50% of PTEN variants tested, located throughout the protein structure, there was strong correlation between instability and dysfunction, resulting in a corresponding range of partial to complete LoF. The consistency of this correlation across models suggests conserved mechanisms for MS-mediated PTEN degradation. For these variants, reduced protein abundance is likely the molecular mechanism underlying dysfunction in each assay, and if consistent under physiologic expression in humans, similar levels of haploinsufficiency may contribute to disease expression.
Other variants, including some exhibiting instability, levels of stability did not correlate with protein function, indicating additional molecular mechanisms underlying dysfunction. 16 variants, including 4A, exhibited more function than expected from their stability, suggesting GoF with or without instability. However, most of these variants exhibited greater dysfunction than expected from their instability. These variants largely localized to well-characterized substrate binding and catalytic domains of PTEN, including the PIP3-binding and N-terminal region of the phosphatase domain, and the catalytic pocket encompassesing the WPD-and P-loops. Phenotypes were typically complete LoF or dominant negative/greater than LoF, rather than partial LoF, indicating that these functional domains are intolerant to modification.
The large number of variants exhibiting dominant negativity in HEK293 cells was unexpected.
While C124S and G129E have previously been established as dominant negatives, such a characterization of other PTEN variants is sparse 15, 21, 56, 57 . Remarkably, we find 29 variants, including 17 ASD, showing dominant negativity in measures of activated AKT. Furthermore, P38S and R130G, two different amino acid substitutions at the same positions as MS variants exhibiting dominant negativity here (P38H, R130L, R130P and R130Q), have previously been reported to have a dominant negative effect on pAKT levels 15, 56 . We also find 6 dominant negative variants not found in ASD, but identified in PHTS and/or somatic cancer. Identifying dominant negative variants is of significant clinical value since they may produce outcomes distinct from LoF variants producing haploinsufficiency. Whether phenotypes identified in an overexpression assay are conserved at physiological levels, as shown for C124S and G129E 56, 57 , requires further study. Overall, these results suggest multiple mechanisms of MS mutation-induced PTEN dysfunction: instability producing haploinsufficiency, and loss of substrate binding or catalytic function leading to either complete LoF or dominant negativity.
We found varied strength of correlations between functional measures of PTEN variants across assays and model systems overall, but high correlations for variants in which dysfunction is due to instability. This suggests conserved mechanisms of MS-mediated protein degradation resulting in reduced protein affecting all assays similarly. Increased intra-assay and -model variability was observed for variants whose dysfunction was associated with mutations in substrate binding and catalytic domains, likely reflecting selective sensitivity of each assay to distinct functions of PTEN. For example, for all 8 sentinel assays in yeast, variants within the WPD were better tolerated than in other model systems, potentially due to differences in steric requirements for interactions with the substrate PI3P in yeast and the primary substrate PIP3 in other models. We also find that the sentinels Δvac14, Δfig4 and Δvac7, which mediate PI3P-to-PI(3,5)P2 interconversion, are particularly sensitive to mutations in the PIP3-binding domain, implicating PTEN-mediated lipid interconversion in these assays. The other 5 sentinels, Δvam3, Δvam7, Δvps30, Δvps38 and Δypt7, are more sensitive to variants located adjacent to the CBR3 loop which mediates PTEN binding to endosomal membrane PI3P 43 , potentially implicating sensitivity to PTEN's role in endosomal trafficking. The fly eclosion assay, however, exhibited heightened sensitivity to mutations in the TI-loop. Other functional domains exhibit conserved sensitivity across models, including the beginning of the phosphatase domain, bordered by variants D22E to R47K and R47W, the PIP3-domain and the P-loop. These results highlight the strength of a multiple-assay and -model system approach for fully assessing variant impact on multifunctional proteins.
Complex patterns of variants' effects on our measures of neuronal morphogenesis and
sensorimotor behavior suggests PTEN has multiple functions in neurons. This is supported by previous findings that both lipid and protein phosphatase PTEN activity participate in synaptogenesis 22, 60 . Here, we find similar patterns of effects on measures of excitatory synaptogenesis and dendritogenesis, indicating common PTEN action. Alternatively, since synapse formation directly affects dendritic growth 61 , their similar patterns of effects may be driven primarily by synaptic changes. Such an interaction would not occur in the axonogenesis assay, since axon growth is measured at stages prior to onset of synaptogenesis. For some variants, results from rat neuronal growth and worm behavior assays differed from yeast and fly assay. For example, H123Q has less impact on the neuronal and behavior assays, while greater impact was seen for a number of ASD variants, including D326N, T167N, I101T, as well as the PHTS variant A79T.
A critical role of functional variomics is establishing whether VUS encode dysfunctional proteins potentially causal to disease, or protein with WT function and likely benign. Given the overlap of specific variants associated with ASD, PHTS and somatic cancer, limited annotation of patient phenotypes, and our inclusion of variants identified in single cases of ASD and PHTS, we could not attribute distinct molecular mechanisms of PTEN dysfunction to distinct disease states.
However, of the 74 variants we tested found in ASD, PHTS, and/or somatic cancer, we find 10 with phenotypes not significantly different from WT, or with >50% WT function in all assays tested. We predict that these variants are likely benign and not contributing to disease. For ASD, the three variants, T78A, T202I and P354Q, show WT activity across assays. P354Q is also the third-most common PTEN variant identified in the population (gnomAD), further supporting its classification as benign. The remaining ASD variants exhibit dysfunction ranging from partial to complete LoF, and dominant negativity. Furthermore, we find a strong relationship between variant impact on multiple assays and their frequency of detection in cancerous tumors. All of the 19 MS variants we examined with at least 8 reports in somatic tumors showed LoF in all highthroughput models, particularly those located proximal to the lipid phosphatase domain.
Altogether, our results strongly support a multi-model system approach for high confidence profiling of genetic variants. functional assays for 106 PTEN variants are summarized according to the following criteria: WTlike variants exhibit no differences to WT, GoF exhibit function values significantly greater than WT, Partial LoF exhibit function significantly greater than null but significantly less than WT, Complete LoF exhibit no differences to null, dominant negative exhibit function significantly less than both null and WT (Below LoF for fly and yeast assays). Classification are based on statistically significant differences of at least p<0.05 compared to the WT-PTEN, null or both.
White cells indicate that the variant was not tested in that assay. b PTEN variant predicted impact based on a binary notation of either LoF (<50% of WT effect) or WT-like (≥50% of WT effect), and classified accordingly based on their frequency of LoF (pathologenic)or WT (likely benign) in 9 assays. . 6a ). b
Data as in (a), removing variants we predict to be benign (Fig. 8b) . Mean PTEN function is plotted as bars ± SEM. * p<0.05, ** p<0.005, *** p<0.0005 by two-way ANOVA. Table 3 .
SUPPLEMENTAL TABLE 1. Annotation of PTEN variants.
SUPPLEMENTAL TABLE 2. Mean and SEM vales for each variant testing in each assay.
SUPPLEMENTAL TABLE 3. Pearson coefficient r and p-values for comparisons between
all assays. SUPPLEMENTAL TABLE 4. C. elegans strains created for this study.
METHODS
PTEN Variant selection and annotation.
We collected PTEN missense and nonsense base substitution variants from VariCarta, SFARI Gene, ClinVar, COSMIC, and ExAC databases and the literature. We used VariCarta to harmonize and annotate the ASD-associated variants. Biochemical Variants were selected from the literature. Population Variants were selected which have relatively high allele frequency in ExAC and/or gnomAD and the absence of disease-association with CADD < 25.
Predicted High Impact or Predicted Low Impact variants were selected based on the CADD phred version 1.0 31 or SNAP2 scores. SNAP2 scores were obtained by correspondence with the authors 1 .
Variants were obtained in an HGVS protein mutation format and back-converted to genomic coordinates using TransVar 2 , using "Reverse Annotation: Protein" mode, GRCH37/hg19 as the reference genome and RefSeq for the annotation database. Resulting genomic coordinates were then annotated using both a local Annovar instance 3 and the wAnnovar web server (ran on June 24th 2019) for additional annotations.
Gene interaction screen in Saccharomyces cerevisiae. The synthetic dosage lethality (SDL)
screen was performed using media and techniques as previously described 4, 5 . The Y7093 strain was transformed with the pGAL1/PTEN plasmid mated to the haploid deletion mutant array at a density of 1536 spots per plate using a Singer RoToR HDA robot (Singer Instruments, Somerset, United Kingdom). The resulting diploids were copied in triplicate onto enriched sporulation medium and incubated at 25°C for 14 days. MATa haploid cells were generated by germination on SC-His/Arg/Lys +Canavanine/Thiamine. Triple mutants were selected by two rounds of incubation on SC-His/Arg/Lys/Ura +Canavanine/Thiamine/G418 medium. A control set of single mutants was generated by two rounds of incubation on SC-His/Arg/Lys +Can/Thia/G418+ 5- 
Multi-Worm Tracker NaCl chemotaxis behavioral assays:
The chemotaxis behavioral assay was conducted as previously described 12, 13 . Briefly, assays were conducted on a 6 cm assay plate (2% agar) where a salt gradient was formed overnight by inserting a 2% agar plug containing 50mM of NaCl (approximately 5 mm in diameter) 1 cm from the edge of the plate. A control 2% agar plug without NaCl was inserted 1 cm from the opposite edge of the plate. Strains were grown on NGM plates seeded with E. coli (OP50) for 3 or 4 days. Worms on the plates were collected and washed three times using M9 buffer before being pipetted onto an unseeded NGM plate to remove excess buffer and select animals carrying transformation markers. Adult worms were transferred and placed at the centre of the assay plates and tracked for 40 minutes on the Multi-Worm Tracker 14 .
After the tracking period, the chemotaxis index was calculated as (A -B)/(A + B), where A was the number of animals that were located in a 1.5 cm-wide region on the side of the assay plate containing the 2% agar plug with 50mM NaCl and B was the number of animals that were located in a 1.5 cm-wide region on the side of the assay plate containing the 2% agar plug without NaCl.
Animals not located in either region (ie. the middle section of the assay plate) were not counted towards the chemotaxis index. One hundred to two hundred animals were used per plate, and two or three plate replicates were used for each line in each experiment. Multi-Worm Tracker software (version 1.2.0.2) was used for image acquisition 14 . Behavioral quantification with Choreography software (version 1.3.0_r103552) used "--shadowless", "--minimum-move-body 2", and "-minimum-time 20" filters to restrict the analysis to animals that moved at least 2 body lengths and were tracked for at least 20 s. Custom R scripts organized and summarized Choreography output files. Each experiment was independently replicated at least twice. No blinding was necessary because the Multi-Worm Tracker scores behavior objectively.
Variant protein abundance measures in Saccharomyces cerevisiae. Yeast were grown overnight under inducing conditions. A600 was measured for all samples then each were diluted to an OD of 0.1 and allowed to grow approximately 6-8 hours or until they reached between 0.8-1.0OD. An equivalent of 1.0 OD was collected for each sample. Samples were pelleted and supernatant discarded before being frozen at -20C. After freezing, glass beads and sample buffer containing sodium dodecyl sulfate (SDS) and 2.0% β-mercaptoethanol were added to the pellet then bead bashed for 2 minutes. Samples were then boiled at 90C for 5 minutes and centrifuged before being loaded into a 4-12% Bis-Tris protein gel (Thermo Fisher Scientific, cat #NP0322) and run with MOPS running buffer (Thermo Fisher Scientific, cat #NP0001). Gels were transferred in buffer containing 20% methanol and 0.03% SDS for 2 hours at 4C at 28V onto 0.2μM nitrocellulose membranes (Bio-Rad, cat #1620097). Membranes were blocked in tris-buffered saline and Tween 20 (TBST) (Acros Organics, cat #AC233360010) containing 5% milk (Bio Basic, cat #NB0669). Membranes were then stained with PTEN antibody (1:1000) (R&D Systems, cat# MAB847,) followed by goat-anti-mouse HRP (Thermo Fisher Scientific, cat#62-6520) and imaged with ChemiDoc MP (Bio-Rad). Membranes were then stripped with a pH 2.2 stripping buffer containing 1.5% glycine, 0.1%SDS and 1% Tween 20 and re-stained for the loading using the anti-glucose-6-phosphate dehydrogenase antibody (Millipore, cat #A9521). Blots were again imaged on ChemiDoc MP (Bio-Rad). Band density was determined using ImageJ. All PTEN bands were normalized first to their loading control then the wildtype PTEN done in each experiment.
All variants were tested in triplicate.
Data modeling and variant effects analysis.
The quantitative phenotypes for the yeast, fly, worm and rat assays were analyzed using a hierarchical (mixed effect) model approach to account for experimental batch effects and variability between replicates. For each assay, we treat the genotype as a fixed effect, which can be either the positive control, the negative control, or a variant, and treat blocking factors such as experimental batch or day as random effects (stratified by variant and accompanying controls). All R scripts are provided at https://github.com/PavlidisLab/Post-PTEN. For each assay, we fit models to the data for all tested variants and accompanying controls jointly. Given a genotype i and a sample j, we fit: , = , , + , , + ∈ Where y is the observed quantitative phenotype (length N where N is the number of data points for the assay in total), X and Z are the model matrices for fixed and random effects respectively, is a vector of parameters for the fixed effects (the genotypes of each variant), u is vector of parameters for random effects, and is residual error. Models were fit using the lmer function of the lmerTest package 15 We then take the y values for each genotype and rescale the data such that the mean positive control equals 1.0, and the mean negative control equals 0.0. Finally, we rescale the standard errors for each genotype from the adjusted data proportionally to the ratio of the adjusted data and the normalized data distributions, thus keeping the values consistent with the 0.0-1.0 re-scaling.
Graphical Analysis. All results are presented as means ± SEM. For HEK293 experiments, data were analysed with Pearson correlations tests and Student's t-tests with WT unless otherwise indicated. All statistical analysis was done using the statistical programming software Graphpad p ≤ 0.05 was considered as significant.
